1. Limitations and opportunities in the pharmacotherapy of ciliopathies
   Max Duong Phu et al, 2021, Pharmacology & Therapeutics CrossRef
2. Effects of Thiazolidinediones on metabolism and cancer: Relative influence of PPARγ and IGF-1 signaling
   Amreen Mughal et al, 2015, European Journal of Pharmacology CrossRef
3. Do metabolic derangements in end‐stage polycystic kidney disease differ versus other primary kidney diseases?
   Magdalena Jankowska et al, 2018, Nephrology CrossRef
4. PPARα agonist fenofibrate enhances fatty acid β-oxidation and attenuates polycystic kidney and liver disease in mice
   Ronak Lakhia et al, 2018, American Journal of Physiology-Renal Physiology CrossRef
5. Metalloproteinase PAPP-A regulation of IGF-1 contributes to polycystic kidney disease pathogenesis
   Sonu Kashyap et al, 2020, JCI Insight CrossRef
6. 17β-estradiol rescues the damage of thiazolidinedione on chicken Sertoli cell proliferation via adiponectin
   Jiao Jiao Zhang et al, 2022, Ecotoxicology and Environmental Safety CrossRef
7. Regenerative potential of platelets in patients with chronic kidney disease
   Elżbieta Cecerska-Heryć et al, 2019, International Urology and Nephrology CrossRef
8. microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism
   Sachin Hajarnis et al, 2017, Nature Communications CrossRef
9. Design and Synthesis of (Z)-5-(Substituted benzylidene)-3-cyclohexyl-2-thioxothiazolidin-4-one Analogues as Anti-Tyrosinase and Antioxidant Compounds: In Vitro and In Silico Insights
   Jeongin Ko et al, 2022, Antioxidants CrossRef
10. Insulin-like Growth Factors and Kidney Disease
    Leon A. Bach et al, 2015, American Journal of Kidney Diseases CrossRef
11. The importance of total kidney volume in evaluating progression of polycystic kidney disease
    Jared J. Grantham et al, 2016, Nature Reviews Nephrology CrossRef
12. Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD)
    Kiyotaka Uchiyama et al, 2021, Clinical and Experimental Nephrology CrossRef
13. Implications of the PAPP-A-IGFBP-IGF-1 pathway in the pathogenesis and treatment of polycystic kidney disease
    Sonu Kashyap et al, 2020, Cellular Signalling CrossRef
14. Glucose and Lipid Metabolism Abnormalities among Patients with Autosomal Dominant Polycystic Kidney Disease
    Magda Fliszkiewicz et al, 2019, Kidney and Blood Pressure Research CrossRef
15. Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney
    Marijn M. Speeckaert et al, 2014, Ageing Research Reviews CrossRef
16. Therapeutic targets for polycystic kidney disease
    Patricia D Wilson, 2016, Expert Opinion on Therapeutic Targets CrossRef
17. Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease
    Thomas Weimbs et al, 2018, Clinical Kidney Journal CrossRef
18. Beneficial effect of combined treatment with octreotide and pasireotide in PCK rats, an orthologous model of human autosomal recessive polycystic kidney disease
    Masanori Kugita et al, 2017, PLOS ONE CrossRef